By
Francesca Gan and Chawanzi Chintu 
Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
| November Rank | October Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 26,905 | 2,065 | 106 |
| 2 | 2 | Johnson & Johnson | 3,008 | 522 | 97 |
| 3 | 3 | AstraZeneca | 2,641 | 375 | 37 |
| 4 | 4 | Merck & Co | 674 | 529 | 122 |
| 5 | 5 | GSK | 631 | 268 | 38 |
| 6 | 8 | Roche | 501 | 164 | 61 |
| 7 | 12 | Abbott | 492 | 452 | 16 |
| 8 | 9 | Sanofi | 346 | 243 | 59 |
| 9 | 10 | Novo Nordisk | 341 | 293 | 24 |
| 10 | 6 | Novartis | 329 | 232 | 53 |
| 11 | 14 | Bayer | 297 | 91 | 16 |
| 12 | 7 | Regeneron | 296 | 60 | 6 |
| 13 | 11 | Gilead Sciences | 240 | 100 | 10 |
| 14 | 15 | AbbVie | 236 | 60 | 13 |
| 15 | 19 | BMS | 232 | 201 | 10 |
| 16 | 16 | Biogen | 210 | 76 | 2 |
| 17 | 18 | Boehringer Ingelheim | 156 | 137 | 39 |
| 18 | 22 | Amgen | 146 | 121 | 6 |
| 19 | 20 | Takeda | 119 | 106 | 18 |
| 20 | 21 | Otsuka | 114 | 3 | 0 |
| 21 | 17 | Lilly | 98 | 55 | 6 |
| 22 | 13 | Fresenius | 81 | 50 | 11 |
| 23 | 28 | Allergan | 79 | 5 | 0 |
| 24 | 24 | Ipsen | 64 | 60 | 5 |
| 25 | 25 | Merck KGaA | 48 | 39 | 18 |
| 26 | 26 | Teva | 46 | 40 | 19 |
| 27 | 33 | Servier | 42 | 34 | 4 |
| 28 | 29 | UCB | 42 | 34 | 11 |
| 29 | 23 | Mylan | 39 | 5 | 0 |
| 30 | 36 | Chugai | 37 | 3 | 3 |
| 31 | 31 | Daiichi Sankyo | 32 | 17 | 5 |
| 32 | 27 | Vertex | 32 | 27 | 0 |
| 33 | 35 | Astellas | 29 | 16 | 2 |
| 34 | 34 | Menarini | 27 | 24 | 6 |
| 35 | 32 | CSL | 22 | 22 | 6 |
| 36 | 30 | Bausch | 19 | 4 | 1 |
| 37 | 37 | Eisai | 12 | 3 | 0 |
| 38 | 39 | Alexion | 12 | 10 | 0 |
| 39 | 40 | Grifols | 11 | 0 | 0 |
| 40 | 38 | Sun | 8 | 2 | 0 |
| 41 | 50 | Mitsubishi Tanabe Pharma | 1 | 1 | 1 |
| 42 | 41 | Aurobindo | 1 | 0 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
| 50 | 50 | Ono | 0 | 0 | 0 |
| 50 | 50 | Endo | 0 | 0 | 0 |
| 50 | 50 | Meiji | 0 | 0 | 0 |
| 50 | 50 | Yunnan Baiyao | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 42 | Sumitomo Dainippon | 0 | 0 | 0 |
The latest insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by healthcare professionals (HCPs) on Twitter during November 2021 were Pfizer, Johnson & Johnson (J&J), AstraZeneca, Merck & Co and GSK.
COVID-19 news, especially regarding the vaccine, drove conversations about the Top 50 Pharmaceutical companies in November. Pfizer, as in previous months, remained at the top of discussions this month, with conversations ranging from positive mentions of the high efficacy of their vaccine in five to 11-year-olds to emerging concerns of data integrity issues found in Pfizer vaccine trials. Pfizer received five times as many mentions as the next company (Johnson & Johnson).
The randomized trial of the Pfizer vaccine for children age 5-11 is published @NEJM today. The data indicate very high efficacy (91%, 95% CI 68,98)) a strong immune response and absence of any serious side effects among 2,268 participants https://t.co/UevcaOWdha pic.twitter.com/7gRgrrMn6c
— Eric Topol (@EricTopol) November 9, 2021
The most shared links by HCPs were about the efficacy and safety of the use of Pfizer’s vaccine in children:
- Study results produced by Pfizer on the effectiveness and safety of their booster jab.
- An Article on the evaluation of the BNT162b2 Covid-19 vaccine on children aged 5-11.
- A BMJ article regarding data integrity issues in Pfizer’s vaccine trial.
COVID-19 made up 63% of the conversations from HCPs about Top 50 Pharmaceutical companies. Drivers were trial results from Pfizer’s oral antiviral treatment for COVID-19 and also their COVID-19 booster vaccine.
Beyond the COVID-19 conversation, HCPs discussed misinformation related to Pfizer’s CEO, Albert Bourla, who was falsely reported to have been arrested.
Pfizer CEO Albert Bourla Was Not Arrested https://t.co/U2QlG8jcQV via @snopes
— Sundar Sankaran (@sundar_s1955) November 6, 2021
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology:
- In November 2021, CREATION Pinpoint® identified 35,443 healthcare professional (HCP) authored tweets from 12,301 individual HCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between November 1st and November 30th 2021.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In November 1,179 of these posts mentioned Janssen.
